Posted by Michael Wonder on 28 Oct 2018
A potent heart drug’s price cut may be a blueprint
27 October 2018 - Slashing the cost of a novel cholesterol drug points a way toward fixing a warped pricing system.
It was a big week for health care, with President Donald Trump’s ambitious new plan to lower drug costs taking centre stage. But there was another big development on the drug-pricing front that may be just as significant.
On Wednesday, Amgen reduced the $14,500 list price of its potential blockbuster cholesterol medicine Repatha by 60%.
